Skip to main content
    H

    Halozyme Therapeutics Inc (HALO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $96.50
    -3.77 (-3.76%)

    Market Cap: $11.43B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Halozyme Therapeutics Inc (HALO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Halozyme Therapeutics reported revenue of $1.40B for the fiscal year ended Dec 31, 2025, up 37.6% from the year before. That year, net income was $316.89M with a net margin of 22.7%, operating cash flow was $651.56M and free cash flow was $644.59M. The quarter ended Sep 30, 2026 had revenue of $492.97M and net income of $247.05M.

    Revenue and Margins

    The operating margin was 33.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $146.69M, a compound annual rate of 28.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.40B+37.6%83.6%33.6%22.7%
    Dec 2024$1.02B+22.4%84.3%54.3%43.7%
    Dec 2023$829.25M+25.6%76.8%40.7%34.0%
    Dec 2022$660.12M+48.9%78.9%40.5%30.6%
    Dec 2021$443.31M+65.7%81.6%62.2%90.8%
    Dec 2020$267.59M+36.5%83.8%53.9%48.2%
    Dec 2019$195.99M+29.1%76.8%-34.5%-36.9%
    Dec 2018$151.86M-52.0%93.3%-45.7%-52.9%
    Dec 2017$316.61M+115.8%90.2%25.6%19.9%
    Dec 2016$146.69MN/A77.4%-56.7%-70.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 28.6% from the year before. In the quarter ended Sep 2026, net income rose 41.0% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.40B$1.02B$829.25M$660.12M$443.31M$267.59M$195.99M$151.86M$316.61M$146.69M
    Cost of revenue$228.77M$159.42M$192.36M$139.30M$81.41M$43.37M$45.55M$10.14M$31.15M$33.21M
    Gross profit$1.17B$855.91M$636.89M$520.81M$361.90M$224.23M$150.45M$141.73M$285.46M$113.48M
    Research and development$366.38M$79.05M$76.36M$66.61M$35.67M$34.24M$140.80M$150.25M$150.64M$150.84M
    Operating income$469.01M$551.48M$337.57M$267.53M$275.90M$144.25M-$67.61M-$69.33M$81.00M-$83.21M
    Net income$316.89M$444.09M$281.59M$202.13M$402.71M$129.09M-$72.24M-$80.33M$62.97M-$103.02M
    EBITDA$582.74M$652.97M$439.73M$327.16M$285.90M$167.94M-$56.54M-$60.91M$87.21M-$63.39M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$492.97M$481.00M$376.71M$451.77M$354.26M$325.72M$264.86M$298.01M$290.08M$231.35M$195.88M$230.04M
    Gross profit$410.50M$401.83M$297.47M$373.00M$299.02M$279.36M$216.46M$255.95M$240.66M$191.75M$167.55M$177.74M
    Operating income$294.97M$287.65M$184.52M-$92.89M$217.92M$202.44M$141.53M$175.50M$163.20M$117.23M$95.54M$101.03M
    Net income$247.05M$229.91M$150.05M-$141.59M$175.22M$165.16M$118.09M$137.01M$137.01M$93.25M$76.82M$85.39M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $2.14B exceeded cash and equivalents by $2.01B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.53B$2.06B$1.73B$1.84B$1.10B$579.92M$565.87M$440.25M$519.95M$261.51M
    Current assets$825.21M$1.09B$746.42M$739.01M$926.29M$554.76M$543.44M$427.85M$510.37M$256.53M
    Cash and equivalents$133.82M$115.85M$118.37M$234.19M$118.72M$147.70M$120.18M$57.94M$168.74M$66.76M
    Total liabilities$2.48B$1.70B$1.65B$1.67B$907.48M$428.88M$474.11M$191.36M$311.58M$294.00M
    Short-term debt$0N/A$6.58M$13.33M$89.42M$397.23M$19.54M$91.51M$77.21M$17.39M
    Long-term debt$2.14B$1.51B$1.50B$1.49B$787.25M$0$383.05M$34.87M$125.14M$199.23M
    Shareholder equity$48.81M$363.82M$83.81M$169.80M$196.95M$151.05M$91.77M$248.89M$208.37M-$32.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$3.47B$2.58B$2.67B$2.53B$2.22B$2.05B$2.20B$2.06B$2.12B$1.97B$1.84B$1.73B
    Total liabilities$3.53B$2.43B$2.45B$2.48B$1.72B$1.72B$1.71B$1.70B$1.67B$1.68B$1.66B$1.65B
    Cash and equivalents$1.03B$163.14M$309.75M$133.82M$419.67M$61.86M$176.33M$115.85M$154.32M$187.86M$164.63M$118.37M
    Shareholder equity-$55.24M$143.54M$219.64M$48.81M$503.92M$332.75M$482.27M$363.82M$452.70M$289.42M$177.81M$83.81M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.9% of operating cash flow. Share repurchases came to 53.1% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$651.56M$479.06M$388.57M$240.11M$299.44M$55.45M-$85.42M-$49.50M$134.05M-$50.38M
    Capital expenditures$6.97M$10.70M$15.29M$4.81M$1.46M$2.50M$4.04M$4.66M$1.54M$3.14M
    Free cash flow$644.59M$468.37M$373.28M$235.30M$297.98M$52.95M-$89.46M-$54.16M$132.51M-$53.52M
    Dividends paidN/AN/A$13.48MN/A$12.54M$63.39M$14.22MN/A$0$0
    Share repurchases$342.37M$250.00M$402.38M$200.00M$350.06M$150.12M$200.00M$0$0N/A
    Investing cash flow-$545.81M-$262.72M-$96.91M-$487.00M-$406.29M$78.35M-$5.55M$2.49M-$163.73M-$76.77M
    Financing cash flow-$85.17M-$218.86M-$407.99M$362.37M$77.86M-$106.28M$153.22M-$63.80M$131.66M$150.62M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$258.27M$240.89M$180.08M$219.03M$178.60M$99.71M$154.22M$178.47M$115.38M$55.79M$129.43M$102.35M
    Capital expenditures$3.05M$4.17M$3.74M$1.43M$3.03M$1.56M$950.00K$3.05M$1.52M$2.58M$3.54M$2.60M
    Free cash flow$255.22M$236.72M$176.34M$217.60M$175.57M$98.15M$153.27M$175.41M$113.86M$53.21M$125.88M$99.76M
    Last 12 quarters

    Frequently Asked Questions About HALO

    What is Halozyme Therapeutics' annual revenue?

    Halozyme Therapeutics reported revenue of $1.40B for the fiscal year ended Dec 31, 2025.

    How fast is Halozyme Therapeutics' revenue growing?

    Revenue was up 37.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 28.4%.

    Is Halozyme Therapeutics profitable?

    Yes. Halozyme Therapeutics reported net income of $316.89M for the fiscal year ended Dec 31, 2025, with a net margin of 22.7%.

    How much free cash flow does HALO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $651.56M minus capital expenditures of $6.97M produced free cash flow of $644.59M.

    How much debt does Halozyme Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $2.14B, short-term debt of $0 and cash and equivalents of $133.82M.